October 12, 2016 10:11 AM EDTUpdated October 13, 11:50 AM

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

Shehla Shakoor

Managing Director

Count Geoffrey Porges in the mix of analysts cheering Ionis $IONS and Biogen $BIIB forward on fresh evidence of the efficacy of nusinersen for spinal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

Shehla Shakoor

Managing Director

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Leerink an­a­lyst ad­justs nusin­ersen peak to $2.5B; Dai­ichi Sankyo signs up to work with Dana-Far­ber team

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings